| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000015194 |
| Receipt No. | R000017663 |
| Official scientific title of the study | Evaluation of Chromosomal Genetic Abnormalities in Cells in Urine Using UroVysion |
| Date of disclosure of the study information | 2014/09/17 |
| Last modified on | 2017/02/10 (Ver. 7) |
| Basic information | ||
| Official scientific title of the study | Evaluation of Chromosomal Genetic Abnormalities in Cells in Urine Using UroVysion | |
| Title of the study (Brief title) | UroVysion Domestic Japanese Clinical Performance Trial | |
| Region |
|
|
| Condition | ||
| Condition | Bladder cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Investigate the utility of UroVysion in detecting bladder cancer recurrence using urine from patients with a history of bladder cance. |
| Basic objectives2 | Others |
| Basic objectives -Others | Accuracy in the diagnosis of bladder cancer |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Sensitivity and specificity in the detection of bladder cancer using UroVysion |
| Key secondary outcomes | 1) Sensitivity and specificity in the detection of bladder cancer using urine cytology
2) The clinical and pathological factors affecting the sensitivity and specificity of UroVysion 3) The clinical and pathological factors affecting the sensitivity and specificity of urine cytology 4) Distribution of the UroVysion determinant factors (aneuploidy in chromosomes number 3, 7, and 17, and deletion of the 9p21 gene locus) in the pathology findings 5) Necessary parameters in the validation study of UroVysion determination criteria 1. Number of cells with increased multiple chromosomes 2. Number of cells with a 9p21 deletion |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Adults of age 20 or older
Patients having a history of bladder cancer within the past 2 years Patients scheduled for cystoscopy and urine cytology exam Consent form obtained |
|||
| Key exclusion criteria | Patients who may be unable to make the follow-up hospital visits
Patients who now have or previously have demonstrable upper urinary tract cancer (renal pelvis or ureter cancer) or urethral cancer (including prostatic urethral cancer) Patients who have already participated in the trial once |
|||
| Target sample size | 450 | |||
| Research contact person | |
| Name of lead principal investigator | Seiichiro Ozono |
| Organization | Hamamatsu University School of Medicine |
| Division name | Department of Urology |
| Address | 1-20-1 Handayama, Higashi-ku, Hamamatsu city |
| TEL | 053-435-2306 |
| oznsei@hama-med.ac.jp | |
| Public contact | |
| Name of contact person | Yutaka Seki |
| Organization | Abbott Japan Co., Ltd. |
| Division name | Molecular Business Development Dept |
| Address | 3-5-27 Mita, Minato-ku, Tokyo |
| TEL | 03-4555-1099 |
| Homepage URL | |
| yutaka.seki@abbott.com | |
| Sponsor | |
| Institute | UroVysion Domestic Japanese Clinical Performance Trial Steering Committee |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Abbott Japan Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | Sensitivity and Specificity |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017663 |